ALLMedicine™ Amyotrophic Lateral Sclerosis Center

Aug 5th, 2022 - Amyotrophic lateral sclerosis (ALS) is the most common neurodegenerative disease of an inflammatory nature among those affecting motor neurons, with a life expectancy of 3 to 5 years. It is characterised by the loss of motor neurons, and can be of...

Aug 5th, 2022 - Studying whether medications act as potential risk factors for amyotrophic lateral sclerosis (ALS) can contribute to the understanding of disease etiology as well as the identification of novel therapeutic targets. Therefore, we conducted a system...

Aug 4th, 2022 - This is a multi-center, two-part study of ION363 in up to 77 participants. Part 1 will consist of participants that will be randomized in a 2:1 ratio to receive a multi-dose regimen of ION363 or placebo for a period of 61 weeks, followed by Part 2...

Aug 4th, 2022 - Over the past decade considerable efforts have been made to accelerate pathophysiological understanding of fatal neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS) with brain banks at the forefront. In addition to exploratory d...

Aug 4th, 2022 - Amyotrophic lateral sclerosis (ALS) impacts bulbar and respiratory musculature, which may contribute to impaired swallow function (dysphagia) and respiratory-swallow coordination. The purpose of this pilot study was to examine if respiratory-swall...

Jan 9th, 2019 - Universally established comprehensive clinical bulbar scales objectively assessing disease progression in amyotrophic lateral sclerosis (ALS) are currently lacking. The goal of this working group project is to design a best practice set of provisi...

Dec 25th, 2017 - Neurological diseases are frequently associated with swallowing disorders and malnutrition. Moreover, patients with neurological diseases are at increased risk of micronutrient deficiency and dehydration. On the other hand, nutritional factors may...

Oct 14th, 2009 - To systematically review evidence bearing on the management of patients with amyotrophic lateral sclerosis (ALS). The authors analyzed studies from 1998 to 2007 to update the 1999 practice parameter. Topics covered in this section include breaking...

Aug 5th, 2022 - Amyotrophic lateral sclerosis (ALS) is the most common neurodegenerative disease of an inflammatory nature among those affecting motor neurons, with a life expectancy of 3 to 5 years. It is characterised by the loss of motor neurons, and can be of...

Aug 4th, 2022 - This is a multi-center, two-part study of ION363 in up to 77 participants. Part 1 will consist of participants that will be randomized in a 2:1 ratio to receive a multi-dose regimen of ION363 or placebo for a period of 61 weeks, followed by Part 2...

Aug 3rd, 2022 - Teva is developing 40 mg/ml Glatiramer Acetate (GA) Injection , administered once daily under the skin, for the treatment of ALS. The study drug is a higher dose formulation of Copaxone® (20 mg/ml GA), a marketed medication, approved for the treat...

Aug 3rd, 2022 - COURAGE-ALS is a Phase 3, double-blind, randomized, placebo-controlled trial of reldesemtiv in patients aged 18 to 80 with ALS. The screening and qualification period for the trial will be no more than 14 days in duration. Approximately 555 eligib...

Aug 3rd, 2022 - Most spinal cord injuries (SCI) are not full transections, indicating that there are residual nerve circuits after injury. Rehabilitation interventions after SCI, including physical training and neural stimulation, have been shown to reorganize mo...

Aug 1st, 2022 - Editor’s note: Readers’ Forum is a department for correspondence from readers that is not in response to articles published in Current Psychiatry. All submissions to Readers’ Forum undergo peer review and are subject to editing for length and sty.

Jul 27th, 2022 - (Reuters) -Biogen Inc's treatment for a rare type of amyotrophic lateral sclerosis (ALS) was accepted for review by the U.S. health regulator, weeks after follow-up analyses of data from a failed late-stage study suggested the drug was likely to w...

Jul 21st, 2022 - The Weekend That I graduated from law school, my mother told me that she had amyotrophic lateral sclerosis, also known as ALS or Lou Gehrig’s disease, a neurological disease for which there is currently no cure. As I recalled in a recent essay, I ...

Jul 6th, 2022 - (Reuters) -The U.S. Food and Drug Administration will reconvene a meeting of its outside experts to review Amylyx Pharmaceuticals' application for its amyotrophic lateral sclerosis (ALS) treatment, the company said on Tuesday. A panel of outside a...

Jun 24th, 2022 - The US Food and Drug Administration (FDA) has unveiled a 5-year strategy aimed at improving and extending the lives of people with rare neurodegenerative diseases. The agency's Action Plan for Rare Neurodegenerative Diseases including Amyotrophic ...